{"organizations": [], "uuid": "db59c4492cdda3e5c6338b907c01f27a20aaf4d2", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-ani-pharmaceuticals-q4-adjusted-no/brief-ani-pharmaceuticals-q4-adjusted-non-gaap-earnings-per-share-1-08-idUSASB0C7PO", "country": "US", "domain_rank": 408, "title": "BRIEF-ANI Pharmaceuticals Q4 Adjusted Non-GAAP Earnings Per Share $1.08", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-02-27T15:37:00.000+02:00", "replies_count": 0, "uuid": "db59c4492cdda3e5c6338b907c01f27a20aaf4d2"}, "author": "", "url": "https://www.reuters.com/article/brief-ani-pharmaceuticals-q4-adjusted-no/brief-ani-pharmaceuticals-q4-adjusted-non-gaap-earnings-per-share-1-08-idUSASB0C7PO", "ord_in_thread": 0, "title": "BRIEF-ANI Pharmaceuticals Q4 Adjusted Non-GAAP Earnings Per Share $1.08", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "ani pharmaceuticals inc", "sentiment": "none"}, {"name": "reuters staff", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "February 27, 2018 / 1:39 PM / Updated 5 minutes ago BRIEF-ANI Pharmaceuticals Q4 Adjusted Non-GAAP Earnings Per Share $1.08 Reuters Staff 1 Min Read Feb 27 (Reuters) - ANI Pharmaceuticals Inc: * ANI PHARMACEUTICALS REPORTS RECORD FULL YEAR RESULTS, REPORTS FOURTH QUARTER 2017 RESULTS, AND PROVIDES 2018 GUIDANCE * Q4 ADJUSTED NON-GAAP EARNINGS PER SHARE $1.08 * Q4 REVENUE ROSE 24 PERCENT TO $47.3 MILLION * QTRLY ‍GAAP NET LOSS INCLUDES IMPACT OF $13.4 MILLION CHARGE DUE TO TAX CUTS AND JOBS ACT​ * QTRLY ‍DILUTED GAAP LOSS PER SHARE OF $0.83​ * SEES 2018 ‍NET REVENUES OF $212 MILLION TO $228 MILLION​ * SEES 2018 ‍ADJUSTED NON-GAAP DILUTED EARNINGS PER SHARE OF $5.43 TO $6.08​ * ‍PLANS TO INVEST APPROXIMATELY $7 MILLION IN CAPITAL PROJECTS DURING 2018​ Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-02-27T15:37:00.000+02:00", "crawled": "2018-02-27T15:46:55.021+02:00", "highlightTitle": ""}